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Abstract
On 7-8th November 2016, 60 people with an interest in the ‘Trials
within Cohorts’ (TwiCs) approach for randomised controlled trial design
met in London. The purpose of this 2nd TwiCs international symposium
was to share perspectives and experiences on ethical aspects of the
TwiCs design, discuss how TwiCs relate to the current ethical frame-
work, provide a forum in which to discuss and debate ethical issues
and identify future directions for conceptual and empirical research.
The symposium was supported by the Wellcome Trust and the NIHR
CLAHRC Yorkshire and Humber and organised by members of the
TwiCs network led by Clare Relton and attended by people from the
UK, the Netherlands, Norway, Canada and USA. The two-day sympo-
sium enabled an international group to meet and share experiences
of the TwiCs design (also known as the ‘cohort multiple RCT design’),
and to discuss plans for future research. Over the two days, invited
plenary talks were interspersed by discussions, posters and mini pre-
sentations from bioethicists, triallists and health research regulators.
Key findings of the symposium were: (1) It is possible to make a
compelling case to ethics committees that TwiCs designs are ap-
propriate and ethical; (2) The importance of wider considerations
around the ethics of inefficient trial designs; and (3) some questions
about the ethical requirements for content and timing of informed
consent for a study using the TwiCs design need to be decided on
a case-by-case basis.
Main report
On 7-8th November 2016, 60 people with an interest in the ‘Trials
within Cohorts’ (TwiCs) design met in London for the 2nd TwiCs
international symposium. The symposium was supported by the
Wellcome Trust and NIHR CLAHRC Yorkshire and Humber and orga-
nised by members of the TwiCs network led by Clare Relton. As
well as UK participants, people came from the Netherlands, Norway,
Canada and USA. Over the two days, the invited plenary talks were
interspersed by discussions, posters and mini presentations from
bioethicists, triallists and health research regulators.
On the first day (7th November, 2016), Jon Nicholl (University of
Sheffield, UK) opened the meeting, welcoming all to the sympo-
sium. He described how the first international symposium in 2014
brought together triallists using the design for the first time, and
led to this, the 2nd symposium which aimed to provide a forum in
which to discuss and debate ethical issues including how the TwiCs
approach relates to the current ethical framework.
What are TwiCs?
Clare Relton (University of Sheffield, UK) set the scene by outlining
the Trials within Cohorts (TwiCs) approach as described in the ori-
ginal article (Fig. 1) in the BMJ in 2010 [1], and the 7 key features of
the design:
(I) Recruitment of a large observational cohort of patients/ people
with the condition of interest
(II) Regular measurement of outcomes for the whole cohort
(III) Capacity for multiple randomised controlled trials over time.
Then for each randomised controlled trial:
(IV) Identification of all eligible people in the cohort
(V) Random selection of some individuals from all eligible people in
the cohort, who are then offered the trial intervention
(VI) Comparison of the outcomes in randomly selected people with
the outcomes in eligible people not randomly selected; that is, those
receiving usual care
(VII) “Patient centred” informed consent; that is, the process of
obtaining information and consent aims to replicate that in routine
health care as far as is possible.
Ethics in current use
Clare described how more than 20 studies using the TwiCs design
now had ethics board approval from boards in Australia, Canada,
Finland, France, Germany, Mexico, Netherlands, Spain, UK, and the
USA. These studies were recruiting cohort populations (e.g. early life,
children and adolescents, young indigenous, adults, older people) in
a variety of settings (e.g., hospital, primary care), in order to facilitate
trials in diverse health areas (e.g., attention deficit hyperactivity dis-
order, breast cancer, colo-rectal cancer, bone metastases, depression,
hepatitis C, HIV, hip fracture, falls prevention, long term conditions,
severe mental illness, scleroderma). Embedded within these cohorts,
there were at least 20 randomised trials testing a wide range of inter-
ventions, and various approaches to informed consent were being
used in these studies.
Jon Nicholl (University of Sheffield, UK) then gave an example of an
emergency medicine research study where it was not possible to ob-
tain informed consent prior to randomisation and have a viable trial,
which illustrated that informed consent for participation in a trial is
not always required. Jon argued that although all trial participants in
TwiCs should receive information about data collection, storage and
sharing and all other non-therapeutic research processes, only those
in the intervention group need to receive information about the
intervention. TwiCs designs randomly select from the cohort and
offer the intervention being tested, those unselected are not actually
allocated to ‘treatment as usual’, so there is no ethical obligation
to tell those unselected about those who were selected, or about
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the treatment they are not being offered. Jon offered the analogy
of lottery winners who are ‘selected’, where there is no sense in
which ticket holders who don’t win are ‘allocated’ to a losers
group. Jon concluded by offering a ‘Sheffield’ position statement
for discussion “In cohort trials, members of the cohort who are not
selected to be offered a new treatment do not need to be told about
the trial intervention (s)”.
Merrick Zwarenstein (Western University, Ontario, Canada) set the
context for the design by clarifying how pragmatic trials provide evi-
dence to inform decision making and explanatory trials test whether
or not an intervention causes an outcome. Merrick suggested that the
PRagmatic Explanatory Continuum Indicator Summary -2 (PRECIS-2)
framework could help designers of TwiCs trials match their design to
their intentions. James Flory (Memorial Sloan Kettering Cancer Centre,
New York, USA) outlined his review [2] of proposals for randomised
controlled trials (RCTs) where randomisation occurred without prior in-
formation being given that interventions would be allocated at random
(Randomisation without Consent). He described 6 different approaches
found in the literature including emergency medicine research, Zelen
designs and TwiCs designs.
The morning session concluded with two researchers reporting their
practical experiences with the TwiCs design and the ethical questions
that were generated and/or resolved through the use of the design.
Rudolf Uher (Dalhousie University, Canada) described the FORBOW
cohort of youth at high risk of severe mental illness and the first RCT
(Skills for Wellness) embedded within this cohort. He described the
advantages of using the design in a situation where most children at
risk were not seeking help. No concerns had been raised about the
TwiCs design during institutional review board process for FORBOW.
Then Anne May (University Medical Centre, Utrecht, Netherlands)
described the exercise-based FIT trial which is embedded within
the hospital-based breast cancer ‘UMBRELLA’ cohort which uses the
staged consent version of the TwiCs design [3]. She highlighted the
possible pros (fast recruitment, no contamination) and cons (non-
acceptance in the intervention group) using the TwiCs design.
Ethical perspectives
The afternoon session began with bioethicist Scott Kim (National In-
stitute for Health, USA) who provided an overview of the ethical
questions that pragmatic RCTs raise and an ethical analysis of two
variations of TwiCs designs, those where information about (and
consent for) future RCTs (i.e. the possibility of being randomised to
the offer of a therapeutic intervention) was provided at enrolment
to the cohort , and those where this information was only provided
after randomisation to those in the intervention group. He con-
cluded with system level ethical questions for broad population
based TwiCs cohorts and learning healthcare systems. This was
followed by Shaun Treweek (University of Aberdeen, Scotland) who
focussed on the wider ethical question of the ethics of inefficiency,
describing the lack of evidence to inform trial process decisions
(e.g. ‘opt out’ vs ‘opt in’ for recruitment), and highlighting the po-
tential waste of resources and participant goodwill. He argued that
inefficiency is an ethical problem and how methodologists must
generate evidence to support their decisions about trial processes.
Tjeerd van Staa (University of Manchester, UK) described how TwiCs
designs are suited for pragmatic trials in the era of big and ubiqui-
tous data collection, but highlighted that refusal of treatment in
the intervention arm could result in bias and loss of power. Andrew
Vickers (Memorial Sloan Kettering Cancer Centre, USA) emphasised
the benefits of integrating patient reported outcomes into routine
clinical practice for optimizing clinical care, reusing these data for
observational and experimental research such as TwiCs, and im-
proving response rates.
Towards the end of the day, Kirsty Wydenbach from the MHRA (Med-
icines & Healthcare products Regulatory Authority) in the UK, empha-
sised that they were familiar with the TwiCs design and that their
main concern was to ensure that participants in TwiCs were aware
that they could withdraw at any time and that the requirements for
safety monitoring were in place. Day one concluded with a speaker
panel discussion on the ethics of whether or not to inform potential
trial participants about interventions that they are not then subse-
quently offered if they are in the control (treatment as usual) group.
Day Two (November 8th, 2016) began with an overview of key find-
ings of the previous day by Helena Verkooijen (University Medical
Centre, Utrecht, Netherlands): including how a case can be made to
ethics committees that TwiCs designs are appropriate and ethical;
the importance of wider considerations around the ethics of ineffi-
ciency; and the range of perspectives on whether upfront informa-
tion on randomisation to future interventions should be given at
enrolment to the cohort. She summarised the discussion as ‘If we
don’t need to, why should we?’ Versus ‘And if we can do it, why
shouldn’t we?’
Regulators perspective
Clive Collett, Ethics Guidance & Strategy Manager at the UK Health
Research Authority (HRA) argued that the methods and procedures
used and the information provided should be proportionate to the
nature and the complexity of the research, and the risks, burdens
and potential benefits (to the participants and/or society) and the
ethical issues at stake. He suggested that the closer the research is to
standard clinical practice, the less need there is to provide patients
and service users with detailed and lengthy information. The legal re-
quirements for non-drug trials are that information must be provided
regarding the broad nature and purpose of the research, the material
and significant risks and benefits and alternatives, but that written
evidence of consent was not legally required. He outlined forth-
coming HRA guidance on applying a proportionate approach to the
process of seeking consent which will allow the consent process to
take place at the consultation using brief information sheets that
promote genuine understanding.
Amanda Hunn, Joint Head of Policy and Public Affairs at the HRA
sketched plans for a survey of Research Ethic Committee (REC)
members in England to explore their appetite for five different
study designs where there was randomisation without prior infor-
mation being given that interventions would be allocated at ran-
dom. Sophie Welch (Independent Ethics Consultant) emphasised
the importance of dialogue with ethics boards, and suggested that
researchers should not avoid the design on the assumption that it
would not secure ethical approval.
Sophie then detailed 5 different questions that ethics committee
members are likely to consider during ethical review: 1) does the
proposed research respect the rights, autonomy, dignity, and well-
being of the participant?, 2) is there a sound ethical basis for this
research design?, 3) based on my experience, what do I think to
this approach?, 4) what are the views of other committee members,
and what guidance and/or regulation can we draw on?, and 5) have
similar research designs already received ethical approval?
Bioethicist Søren Holm (University of Manchester, UK) explored
why and when control groups should consent and whether ethical
considerations relating to harm, burden, rights and reasonable ex-
pectations help us to answer this question. He concluded his talk
with an exploration of what might be the reasonable expectations
from the ordinary understanding of the patient-healthcare provider
relationship.
Engagement with ethics committees
The morning session concluded with two researchers describing their
experiences of using the TwiCs design and the ethical questions
that were generated and/or resolved through use of the design.
Linda Kwakkenbos (McGill University, Canada), reported that the
Scleroderma Patient-centered Intervention Network (SPIN) Steering
Committee and Patient Advisory Board liked that the TwiCs design
was providing a sustainable framework for multiple trials of inter-
ventions for the rare disease scleroderma, and that the design did
not engender disappointment for those patients not receiving
intervention. Since the start of enrolment in the SPIN Cohort more
than 1500 patients with the rare disease scleroderma had been en-
rolled from 39 centres in 5 countries after obtaining approval from
the local ethics board for each centre.
Sophie Gerlich (University Medical Centre, Utrecht, Netherlands) dis-
cussed preliminary results of her study of patient understanding
and opinions regarding informed consent with data drawn from
questionnaires to patients who had either agreed or declined to
participate in three cohorts using the TwiCs design – colorectal can-
cer, breast cancer and bone metastases.
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After the lunchtime poster presentations, Danny Young-Afat (Univer-
sity Medical Centre, Utrecht) introduced the afternoon session which
was devoted to 8 mini talks on future directions for empirical and
conceptual research in relation to the TwiCs design. The session
began with Joanne van der Velden (University Medical Centre, Ut-
recht) discussing the interim results regarding recruitment and ran-
domisation for their ongoing Vertical RCT embedded in the PRESENT
bone metastases cohort. She noted that these compared favourably
to a classic multi-centre RCT in the same patient population which is
running simultaneously in the Netherlands.
Future research
The remaining sessions explored future plans relating to the TwiCs
design with a focus on ethical aspects. Petter Viksveen (University of
Stavanger, Norway) outlined early plans to set up a mental health co-
hort for adolescents in Norway. Joanne Zakrewska (Pain Management
Centre, UCLH NHS Foundation Trust, London, UK) argued for the need
for a cohort study using the TwiCs design to facilitate the testing of sur-
gical and pharmacological interventions for patients suffering from Tri-
geminal Neuralgia. Amanda Hunn (Health Research Authority (HRA),
UK) described HRA plans to set up a special panel to give endorsement
for registries that recruit patients into research (this includes ‘consent
for consent’ and ‘consent to be approached’ registries such as the York-
shire Health Study and Health Wise Wales). Panel endorsement of regis-
tries would mean that a study using an endorsed register/cohort to
recruit would not require the ethics board to look at the recruitment
process again as it would already have been endorsed by the HRA. An-
drew Vickers (Memorial Sloan Kettering Cancer Center, USA) discussed
the overzealous approach to autonomy of standard informed consent
procedures and the harm which often arose from information overload
for those patients randomised to usual care. He illustrated this with
an example of a trial where late stage cancer patients make heart
wrenching decisions about whether to risk possible side-effects for
uncertain harms and then for 50% of the patients then randomised
to usual care, this agonizing consent process makes no difference
to their care and they could have been spared considerable anxiety
and decisional burden. He argued for empirical research to docu-
ment any consent-related distress and how this might be amelio-
rated by alternative approaches such as the TwiCs patient centred
approach to informed consent.
The session concluded with three proposals for further research from
Clare Relton (ScHARR, University of Sheffield). The first suggestion was
to compare the efficiency and acceptability of two different Informed
Consent pathways (Standard vs Tailored) for effectiveness trials with
‘usual care’ comparators. Efficiency would be measured using the ratios
of numbers analysed, to the numbers: (i) approached, (ii) randomised,
(iii) allocated to the intervention, (iv) accepting their allocation; as well
as the representativeness of the population recruited, and the time
taken and cost incurred. The second suggestion was to introduce an
‘Information and Consent’ extension to the CONSORT flow diagram
and/or statement, and the third was to explore the potential of the
TwiCs approach to transform healthcare systems into learning health-
care environments – linking up existing cohorts or even building a UK
NHS based national cohort.
Day two concluded with a lively and wide ranging panel discussion
with many contributions from the audience including the announce-
ment that £1.1mn NIHR funding had just been obtained for a TwiCs
designed study which was trialling a range of investigational medicinal
products. The panel acknowledged that it was clearly possible to make
a compelling case to ethics committees that TwiCs designs were appro-
priate and ethical; the importance of wider considerations around the
ethics of inefficient trial designs; that there was broad consensus from
those attending the symposium that there were no hard and fast rules
regarding the informed consent processes relating to therapeutic pro-
cesses (interventions, randomisation), and that some key ethical ques-
tions about the content and timing of informed consent for a TwiCs
may need to be decided on a case-by-case basis.
The slides and films from the TwiCs Ethics symposium can be viewed
at https://www.twics.global/ethics-symposium-2016
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ABSTRACTS
Topic 1: Context
A1
TwiCs RCTs can be explanatory, pragmatic or in-between
Merrick Zwarenstein (merrick.zwarenstein@ices.on.ca)
Schulich School of Medicine & Dentistry, Western University, London,
Ontario, N6A 3K, Canada
Trials 2017, 18(Suppl 2):A1
Randomised controlled trials (RCTs) using the TwiCs design streamline
patient recruitment by tailoring and staging consent, allow for testing
of multiple interventions against a common control group, and inte-
grate evaluation into the natural flow of care. Are they pragmatic?
Schwartz and Lellouch [1] identified two opposite attitudes or purposes
to RCT design: to provide evidence which supports a clinical, service
delivery or health policy decision (the “pragmatic” attitude) or to ex-
plore a mechanism of action of the intervention under study (by testing
whether or not it causes an outcome -the “explanatory” attitude).
These attitudes are not dichotomous, but represent opposite ends
of a spectrum. The Pragmatic Explanatory Continuum Indicator
Summary second generation tool (PRECIS-2) [2] operationalises the
pragmatic/explanatory spectrum as 9 domains (Table 1), each
reflecting an aspect of RCT design, each rated on a 5 point scale for
similarity to usual care, as ordinarily provided in the clinical settings
in which the intervention is intended to be used after evaluation in
the planned RCT.
Fig. 1 (abstract I1). The ‘cohort multiple randomised controlled
trial” design – BMJ
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PRECIS-2 can be applied to all trials, including TwiCs trials, in order to
help designers match the design of their trial to their intended use
for the trial results. For example, the position on the PRECIS-2 scale
for eligibility of a TwiCs RCT of treatments at a breast cancer clinic
would be determined by how the control and intervention partici-
pants are selected from the entire cohort: more pragmatic if all clinic
patients are included in the trial and if a representative subsample is
selected for intervention, or more explanatory, if tight inclusion criteria
exclude many clinic patients from the trial participants. This design
choice can be repeated for the other eight PRECIS-2 domains.
References
1. Schwartz, D., Lellouch, J. (1967), ‘Explanatory and pragmatic attitudes in
therapeutic trials’, Journal of Chronic Disease,20, 637-48.
2. PRECIS-2 https://www.precis-2.org/
A2
Ethical Issues in Trials within Cohorts and other Pragmatic RCTs
Scott Kim (scott.kim@nih.gov)
Department of Bioethics, National Institutes of Health, Bethesda, MD, USA
Trials 2017, 18(Suppl 2):A2
The pragmatic imperative in clinical trials implies designing trials
that mimic the day-to-day operations of the clinic, creating unique
ethical questions that are shared by different types of pragmatic
studies. In RCTs that compare two standard of care treatments, all
patients inside the RCT receive ‘accepted standard treatments’ yet
this does not imply there is minimal risk or that no consent is re-
quired [1]. In Trials within Cohorts (TwiCs), an RCT can be conducted
in which the control groups receives just normal clinical care, with-
out any experiences or changes to their care caused by the RCT.
How does this difference affect the requirements of informed con-
sent for TwiCs?
Intentionally withholding information about future randomisation
and use of data—when it could be disclosed without detriment to
the RCT—may run the risk of violating reasonable expectations of
patients and compromising the trust that is so necessary for a stable
program of pragmatic trials. This concern could be addressed in co-
horts with TwiCs by disclosing information and obtaining permission
from cohort participants ahead of time, in anticipation of future
cohort-embedded RCTs. However, there is no widely accepted stand-
ard for the content of such prior disclosure and consent. Some inves-
tigators rely on non-TwiC specific general permission about ‘future
use of data’ while others use pre-randomisation broad consent that
includes explicit information about future randomised TwiCs (includ-
ing information on randomisation, potential for future contact for the
intervention arm, and use of data without further notification in con-
trol arm) [2]. For the time being, which of these options to use must
be evaluated for each trial by considering the nature of the cohort,
the interventions to be tested, and the reasonable expectations of
patients in that context. However, the growing field of TwiCs may
benefit from a more generalizable model of ethical analysis regard-
ing the content and procedures of prior broad consent for TwiCs.
References
1. Chen SC, Kim SY. A framework for analysis of research risks and benefits
to participants in standard of care pragmatic clinical trials. Clinical Trials.
2016;13(6):605-611.
2. Young-Afat DA, Verkooijen HM, Van Gils CH, et al. Staged-informed
consent in the cohort multiple randomised controlled trial design.
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A3
Randomisation without Consent
James Flory, Zachary Goodman
Cornell University (Weill Cornell Medical College), Ithaca, NY, USA
Correspondence: James Flory (jaf9052@med.cornell.edu)
Trials 2017, 18(Suppl 2):A3
Informed consent to research is acknowledged to be a burdensome
process for both researchers and participants. Various efforts have
been made to improve it, including shorter consent forms, abbrevi-
ated oral consent, staged consents, and even omission of consent
entirely. The last approach (‘randomization without consent’ or
RWOC) is the most controversial.
Our review identified ten distinct designs for RWOC, falling into three
general categories [1]. First are studies in which informed consent is
not obtained because it is infeasible. The clearest example is emer-
gency research, when extremely ill patients must be assigned treat-
ment under rushed circumstances that preclude obtaining consent.
Some forms of cluster randomized studies also fit this category.
A second category is studies in which consent is feasible, but arguably
ethically unnecessary because the risk to participants from participation
in a particular study is very low. A further argument is that consent re-
quirements actually do harm in these cases, by making it more difficult
to conduct very safe studies that stand to benefit patients by better
informing clinical care. These proposals have been strongly criticized
on the grounds that they deceive patients and disrespect patient
autonomy [2]. Recent proposals of this type have focused on the
possibility that they can be more ethically conducted in the context
of a learning healthcare system [3].
A third category is known variously as ‘post-randomization consent’
or ‘Zelen’ designs. There are several versions of this design. But, the
fundamental concept is that while patients who receive experimental
interventions should give consent, patients who receive usual care as
part of the control group may not need to consent. Indeed, in some
cases asking patients in the control group for consent may create
distress and disappointment without clear benefits to patients. Post
randomization consent designs have generally attracted ethical scrutiny
and criticism, and remain fairly rare in practice.
The TwiCs design (referred to in our original review as cohort multiple
RCT [cmRCT]) is closely related to other post-randomization consent de-
signs. A crucial design issue in a TwiCs is whether patients who are en-
rolled in a cohort give a broad consent that explicitly mentions future
randomizations. If so, TwiCs is not RWOC, but a form of staged consent.
The ethical arguments and intuitions as to whether a given imple-
mentation of TwiCs should mention randomization in the initial
broad consent may vary significantly depending on the specific
clinical question and context.
References
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Table 1 (abstract A1). Attitude of RCTs: Domains of PRECIS2
1. Eligibility: How similar are trial participants to those in intended usual care?
2. Recruitment: Is trial recruitment process similar to that of entry into usual care?
3. Setting: How similar is the trial setting to the intended usual care setting?
4. Organisation: Are resources added for care in the trial beyond those in usual care?
5. Flexibility-delivery: Are clinicians constrained differently from usual care?
6. Flexibility-adherence: Are participants selected, burdened beyond usual care?
7. Follow up: Are participants followed up more closely that in usual care?
8. Primary outcome: How similar are trial outcomes to usual care criteria for success?
9. Primary analysis: Are all participants included in the main analysis?
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A4
Why and when should control groups consent? Do ethical
considerations relating to harm, burden, rights and reasonable
expectations help us to answer this question?
Søren Holm1,2,3 (soren.holm@manchester.ac.uk)
1Centre for Social Ethics and Policy, School of Law, University of
Manchester, Manchester, UK; 2Centre for Medical Ethics, HELSAM,
University of Oslo, Oslo, Norway; 3Department of Health Science and
Technology, Aalborg University, Aalborg, Denmark
Trials 2017, 18(Suppl 2):A4
Informed consent in research ethics is a ‘technology’ designed to
protect a number of basic ethical values. This talk outlined four sets
of considerations that all lend support to a consent requirement
(see below) and explored their implications for consent of control
groups in Trials within Cohorts designs (TwiCs).
The most general justification for consent is that participants need to
know that they are part of research and need to agree to this. But in
standard clinical research, e.g. randomised controlled trials there are
further reasons why we require consent from both the intervention
and the control group. Control group participants in standard clinical
research rarely receive ‘standard treatment’, i.e. the treatment they
would have had if they were not research participants. Their treat-
ment is often precisely specified and they are subject to additional
diagnostic tests. This is one of the main reasons for seeking informed
consent. Consent is needed if the research involves: 1) additional risk
of harm, 2) additional burden, 3) infringement of rights relating to
self-determination, privacy or bodily integrity, or 4) something that
breaches the reasonable expectations of participants in relation to
their contact with health care professionals.
A TwiCs trial can be designed so that there is no additional risk or
burden because nothing changes for the control group; and all par-
ticipants consent to the use of their data when entering the cohort.
The need for informed consent from the control group can there-
fore, to a large extent be ‘designed out’, if the initial information to
cohort participants explains the embedding of future trials in the
cohort and no attempts are made to standardise the treatment of
control group participants once they have been allocated to the
control group.
A5
The ethics of inefficiency
Shaun Treweek (streweek@mac.com)
Health Services Research Unit, University of Aberdeen, Aberdeen, AB25
2ZD, UK
Trials 2017, 18(Suppl 2):A5
Background
Trials are important but they are sometimes inefficient. If inefficiency
means that a trial has poor or irrelevant research questions, has
made design choices that reduce relevance, has design inefficien-
cies that mean the trial cannot answer its research questions, or
uses more resources than it needed to, then important ethical
questions are raised.
Discussion
Broadly speaking, we can define two types of efficiency: scientific
and process. Scientific efficiency is about choosing the right research
questions and then the right design to answer those research ques-
tions. Scientific inefficiency can fatally wound a trial long before it
comes into contact with a participant. For example, many trials are
started in complete ignorance of earlier trials or systematic reviews
that are highly relevant to the design decisions of the new trial, in-
cluding whether the new trial is needed at all. This is a major eth-
ical failure. Poor choice of outcomes or participants can render the
results of an otherwise well-done trial irrelevant to the decisions it
was intended to support.
Process efficiency is about proper planning and doing what you
need to do to answer the research questions, and no more. Lack of
evidence to inform trial decisions means that remarkably few trial
process decisions can be described as evidence-informed. This
process inefficiency wastes resources, adds burden to health re-
search infrastructure and spills participant goodwill, again raising
ethical questions. The TwiCs approach to pragmatic trial design is
potentially more efficient than the standard approach pragmatic
RCT design in a number of ways. For example, embedding trials
within large observational cohorts can facilitate (i) fast and efficient
recruitment of participants, (ii) collection of long term outcomes
and (iii) enables the use of unequal randomisation (improving the
efficiency of trials of high cost interventions compared with equal
allocation).
There can be a tension between the ethics of making a design or
process choice and the ethics of not making that same choice (opt
in versus opt out for recruitment is an example, or the use of tele-
phone reminders to non-responders). Ethical judgements need to
consider this balance, not just the ethics of the initiative being
proposed.
Conclusion
Inefficiency in research is an ethical problem. Trialists need to identify
existing research before starting their trial design, and think carefully
about who their trial is for so as to avoid irrelevance. Ethics and other
governance structures need to ensure that this is done before grant-
ing approvals. Methodologists need to generate more evidence to
support trial design and process decisions. Initiatives such as Trial
Forge (http://www.trialforge.org) and the REWARD Alliance (http://
rewardalliance.net) have important roles to play in this endeavour.
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Background
Some ethical concerns have been raised following the introduction
of the cmRCT design. This abstract addresses patients’ perspectives
and understanding of the cmRCT design.
Method
At the University Medical Center Utrecht, patients with colorectal
cancer, breast cancer and bone metastases are recruited into cohorts
with a cmRCT design. In these cohorts, several trials are running. Self-
administered questionnaires were used to evaluate patients’ opinion
and understanding of the cmRCT design at several stages of cohort
participation, i.e. shortly after agreeing to (n = 312) or declining (n = 84)
cohort participation, after enrolment in a cohort based trial (n = 35),
after declining participation in a trial (n = 20) and one to eight months
after cohort enrolment (n = 56).
Results
This quantitative study is based on 507 returned questionnaires. Almost
all patients (94%) indicated altruism as the main reason for cohort par-
ticipation. Shortly after enrolment 5% (14/304) of patients did not re-
member whether they had agreed to future randomisation and 50
patients (16%) recalled this decision incorrectly. One to eight months
after enrolment, 29% (16/56) did not remember agreeing to future ran-
domisation, and 30% who thought not to have given permission for
randomisation actually did. Shortly after enrolment, 35% (75/217) of pa-
tients who gave permission for randomisation hoped to receive an invi-
tation for an experimental intervention. Forty-two percent (23/55) of
patients who were offered an experimental treatment understood that
selection for experimental interventions was based on chance, whereas
46% (25/55) of patients were not interested in understanding the selec-
tion procedure.
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Conclusion
Altruism was the most important motivation for patients to partici-
pate in the cohorts. Some misconceptions exist regarding compo-
nents of informed consent. However, these misconceptions do not
seem to be more prevalent in cmRCT than in standard RCTs.
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Study Design
This study will recruit newly diagnosed psoriatic arthritis (PsA)
patients. The cohort will receive best practice therapy following
European Recommendations: a “treat to target” approach where
treatment is escalated aiming for an objective target. Treatment
will be escalated from one standard disease-modifying agent
(DMARD), combination DMARDs and finally to biologics.
Two initial studies are planned. A randomised feasibility study will as-
sess whether patients with mild PsA could be treated conservatively
without DMARDs. A powered trial in moderate/severe PsA with two
interventional arms will test more intensive drug therapies within the
treat to target approach. One arm will receive combination DMARDs
from the time of diagnosis, the other arm will receive an initial
6 month course of biologics tapering to DMARDs after this.
Ethical issues raised by the TwiCs design
The TwiCs design was chosen to allow analysis of real life outcomes
in the cohort and treatment comparisons in the trials, producing
generalizable results with the aim of changing routine practice.
Positive ethical issues
It will not be practical to “blind” therapy in these studies. This raises
the issue of disappointment bias in patients who receive the “treat-
ment as usual” comparator if they are aware that they have not
been given the more intensive treatment. The use of the TwiCs de-
sign will avoid any disappointment bias allowing accurate compari-
sons of treatment.
Ethical issues of concern
The two stage consent for the cohort and then potentially for an
interventional study must occur prior to starting treatment in newly
diagnosed patients. Appropriate assessment at baseline in the co-
hort will have to rapidly allow randomisation to interventions and
the consent forms and information given will have to be easily
understandable to the patients to avoid overwhelming them.
In a usual RCT design, only patients consenting to the interventional
study would be included in an intention to treat analysis. Whilst we
plan to use complex statistical methods to adjust for the patients
offered the intervention but declining (based on CACE analysis), a
low consent rate for the offered interventions may affect our later
analysis.
The studies planned within the TwiCs are both controlled trials of
investigational medicinal products. As patients within the cohort
will be acting as a “control” group for the interventions, additional
detailed information relating to adverse events will have to be col-
lected in the cohort beyond that which would normally be col-
lected in a cohort placing an additional burden on these patients.
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The Community Ageing Research 75+ (CARE 75+) study is using a Trials
within Cohorts (TwiCs) design to build ageing research capacity. TwiCs
is also considered a useful method for recruiting potentially hard to
reach groups such as people with frailty1. As part of the NIHR Collabor-
ation for Leadership in Applied Health Research and Care Yorkshire &
Humber (NIHR CLAHRC Y&H), CARE 75+ is recruiting community-
dwelling older people (≥75 years) from across the UK (n =280) . The
primary objective is a prospective epidemiological analysis of frailty,
disability and quality of life trajectories with health, social and eco-
nomic data captured at baseline, 6, 12, 24 and 48 months.
There are recognised challenges of using a multiple studies platform
which have relevance for other researchers studying frailty, disability
and cognitive impairment. We have observed that the initial cohort
consent procedure is more complex and time-consuming than usual
as researchers explain about requests for future study participation
and that their data may be used as control data. We have also ob-
served confusion between involvement the CARE 75+ observational
study and involvement in sub-studies with participants sometimes
not recognising the discrete nature of different studies.
To meet these challenges we have worked alongside our theme-wide
patient and public group, the Frailty Oversight Group (FOG)2. Firstly,
the FOG have scrutinised all sub-studies at the outset to ensure there is
no unnecessary burden for participants, such as replication of outcome
measures. Secondly, the FOG have observed researchers undertaking
consent and assessments to improve the process from the participants’
perspective. Thirdly, we inform all participants of new up-and-coming
studies by newsletters but stagger invitations to ensure equal access
whilst not overburdening them with information. We will continue to
work with the FOG to assist with improving branding of information
sheets and consent forms to ensure clarity and discrimination between
CARE 75+ and sub-studies. To date, 83% of CARE 75+ participants
agreed to contact about future studies (e.g. qualitative research and
pilot work for future randomised controlled trials).
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Background
Poor populations face the greatest burden from disease and disability
[1] but medical research priorities are driven largely by the global mar-
ket for treatments [2]. Consequently, the healthcare needs of people in
low and middle income countries (LMICs) are often neglected. There is
an urgent need for more pragmatic research in LMICs but clinical trials
in LMICs are highly sensitive to what the European Commission de-
scribes as ‘ethics dumping’. Due to the progressive globalisation of
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research activities, there is a risk that research that would not be
ethically permissible in the European Union is exported to countries
where the legal and regulatory framework for research is not as
stringent [3]. The Trials within Cohorts (TwiCs) study design offers
the real world applicability of results that is desperately needed in
LMICs. However, for the TwiCs design to be of value in LMICs there
must be care to avoid ethics dumping with sensitivity to local pref-
erences, needs and environment.
Method
A broad based consultative exercise was undertaken to identify and
analyse vulnerabilities for exploitation (ethics dumping) in research
in LMICs. Data was garnered from multi-level ethics bodies, policy
advisors/makers, civil society organisations, funding organisations,
industry and academic scholars, more than 30 members of ethics
committees in LMICs, representatives from vulnerable populations in
LMICs and an open call for case studies of ethics dumping in LMICs.
Results
A wide variety of vulnerabilities were identified and analysed themat-
ically. For example, those who live in poor circumstances are more
vulnerable to undue inducement and those who lack education may
struggle to understand the research information. Cultural differences
can influence the interpretation of certain ethical principles and a
lack of resources and infrastructures can seriously affect the validity
of the research. Additionally, many studies lack relevance for the
communities in which they are undertaken and offer no potential for
benefit from the results; this can leave the participants with a sense
of being used or abused.
Conclusion
The logistical and ethical challenges for the conduct of any cohort
studies in LMICs are significant. Community engagement and local
ownership are essential for sustainability and the research may re-
quire significant investment in the local community. The TwiCs de-
sign offers a means of ensuring that studies are relevant to specific
communities and as such, may be of great value in LMICs.
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Severe mental illness includes schizophrenia, bipolar disorder and
the most severe cases of depression. The Families Overcoming Risks
and Building Opportunities for Well-being (FORBOW) program aims
to find out how we can effectively prevent severe mental illness
through early indicated interventions. The Trial within Cohorts
(TwiCs) design makes it possible to test the long term effect of in-
terventions with strong external validity.
FORBOW enrols children and youth (age 1-21 years) in an accelerated
cohort with annual assessments of cognitive development and psy-
chopathology [1]. Youth participants are recruited through their
parents, with an oversampling of parents who are receiving health
services for severe mental illness, irrespective of whether any psy-
chopathology is present in the youth. To date, we have enrolled
317 participants in the cohort and we have been able to follow-up
95% of cohort participants annually. The combination of family his-
tory of severe mental illness and early antecedents including
affective lability, anxiety, psychotic symptoms and basic symptoms
allows efficient early identification of risk.
Embedded within the cohort is a trial of Skills for Wellness (SWELL),
a psychological early intervention which coaches children and ado-
lescents in coping and emotional skills needed to develop resilient
mental health. Eligible participants who are 9-21 years old and
present with one or more antecedents are randomly allocated to
be offered the SWELL intervention or not in a 1:1 ratio. The partici-
pants are not actively seeking treatment at the time of allocation.
To date, 36 participants have been randomly allocated and the
intervention participation rate has been 83% with positive feedback
from participating families. This contrasts with experiences from an-
other early intervention trial in a non-help seeking population that
had similar aims but followed traditional clinical trial design and
was stopped because of failure to enrol participants [2,3]. The early
experience suggests that the TwiCs design enables externally valid
tests of preventive interventions with long-term follow up.
Trial registration:
ClinicalTrials.gov Identifier: NCT01980147
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Introduction
Exercise interventions show beneficial effects on cancer patients’
quality of life. However, effect sizes are often small, which might be
partly explained by contamination; i.e., patients randomised to the
control arm adopt the exercise intervention. Also, patients may re-
frain from participation, or drop-out after being randomised to the
control arm. Applying a cohort multiple RCT (cmRCT) design might
overcome the disadvantages of conventional RCTs when blinding of
the intervention is impossible. UMBRELLA FIT studies the feasibility of
cmRCT in exercise-oncology research. Effects of the intervention on
quality of life will be investigated.
Methods
The ‘Utrecht cohort for Multiple BREast cancer intervention studies
and Long-term evaluation (UMBRELLA cohort)’ started in 2013 in the
UMC Utrecht (The Netherlands). Currently >1600 breast cancer pa-
tients participate. Over 85% provided broad consent to be randomly
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selected for future experimental interventions or to serve as control
without further notice. For the UMBRELLA FIT study, 168 physically
inactive breast cancer patients (12-18 months post-baseline), who
gave broad consent are randomised to a 12-week supervised exer-
cise intervention or control. Endpoints are contamination, partici-
pation, generalizability and retention (methodological) and quality
of life (effectiveness). In addition, instrumental variable analysis will
be performed taking drop-out/non-compliance after randomisation
into account.
Results
The UMBRELLA FIT trial recruitment started in October 2015, since
then 130 patients have been randomised. Of 65 intervention pa-
tients, 55% agreed to participate. Reasons for non-participation
were mainly time constraints, dislike of exercise, or avoidance of
confrontation with their disease. Acceptance rate of the interven-
tion has been lowest in the summer period.
Conclusion
It is anticipated that recruitment will be completed in 2017. Results
on feasibility and effectiveness will be reported.
Trial registration
The Netherlands National Trial Register NL.52062.041.15 / NTR5482
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Clinicians routinely collect information on patient-reported outcomes
as a part of clinical care. For instance, a rheumatologist will want to
understand a patient’s level of pain and functioning in order to con-
sider the effectiveness of a new treatment; a cancer surgeon will
want to know how a patient is recovering from surgery in order to
determine whether persistent symptoms require attention. There are
numerous reasons why the use of standardized questionnaires for
such purposes is far superior to informal discussion.
At Memorial Sloan Kettering Cancer Centre (MSKCC) we have pio-
neered the use of electronic methods to gather patient-reported
outcomes as part of standard care. Current clinical projects include
urinary and erectile function after radical prostatectomy; pain and
recovery after gynaecological surgery; bowel, urinary and sexual
function after rectal surgery; patient satisfaction with breast recon-
struction; gerontology; pain and discomfort during prostate biopsy.
We ensure that clinical staff are involved in the development of the
questionnaire, the design of the report given to clinicians summar-
ising patient responses and its integration into clinical workflow. By
optimizing the clinical value of patient-reported outcomes we en-
sure that patients do indeed complete them in routine practice.
Data obtained to aid the clinical consultation can then be reused as
the endpoints of randomised trials, facilitating the sort of clinically-
integrated research associated with many TwiCs approaches. For in-
stance, we are currently conducting a traditional randomized trial
comparing two approaches to port-site closure after minimally-
invasive surgery, using patient-reported hernia as an endpoint. The
critical point is that all of our patients are asked to provide data on
hernia, whether or not they take part in the trial. Hence, although
our trial is not in a TwiCs context, it demonstrates how use of rou-
tinely collected patient-reported outcomes can facilitate the sort of
low-cost, pragmatic trials common in TwiCs.
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Background
People with rare diseases do not typically have access to evidence-
based self-management and psychosocial interventions, and
conducting rigorous, adequately powered trials is difficult. The
Scleroderma Patient-centered Intervention Network (SPIN) is a
collaboration of scleroderma centers, clinicians, patient organiza-
tions and investigators from Canada, the US, Mexico and Europe,
whose aim is to develop, test, and disseminate self-management
and psychosocial interventions for people living with the rare
disease scleroderma [1].
Methods
SPIN utilizes the cohort multiple RCT (cmRCT) design to collect lon-
gitudinal data on patient-reported outcomes in scleroderma via the
Internet and to test online interventions on an ongoing basis. SPIN
is in the process of enrolling 2,000 scleroderma patients for an on-
going web-based cohort dedicated to better understand problems
important to scleroderma patients, validating outcome measures,
and informing development of interventions. SPIN will also use the
cohort framework to develop, evaluate, and deliver the online sup-
port tools. Eligible participants are at least 18 years of age, have a
scleroderma diagnosis, speak one of the SPIN languages (currently
English, French or Spanish) and have access to the Internet. Upon
enrolment in the Cohort, participants allow their physician to pro-
vide their contact information and basic medical information to the
SPIN team. Once participant’s medical data are entered online, they
receive emails at 3-month intervals that invite them to complete
online assessments. The cmRCT design allows us to recruit very
large samples for trials, even in a rare disease context, and reduces
the cost of re-starting the recruitment process each time, including
getting new ethics approval for each participating center.
Results
Since enrolment started in April 2014, SPIN has recruited over 1,500
scleroderma patients from 39 centers in Canada, the US, the UK,
France and Mexico after obtaining approval from the local ethics
board for each center. SPIN was recently funded to evaluate the ef-
fectiveness of an online hand exercise program and a scleroderma
disease self-management program in two pragmatic RCTs embedded
in the SPIN Cohort, including 400-500 patients in each. For these tri-
als that SPIN will run through the Cohort, ethics approval is only re-
quired from the SPIN coordinating center at the Jewish General
Hospital of McGill University, which adds to the feasibility of conduct-
ing multiple trials.
Discussion
The use of the cmRCT design and development of self-guided
eHealth interventions allows SPIN to develop, rigorously test, and
deliver interventions for people with a rare disease from around
the world.
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Introduction
Many patients with cancer develop painful bone metastases which
are a poor prognostic sign. About 60% of patients undergoing stand-
ard radiotherapy experience (partial) pain relief [1]. Stereotactic radio-
therapy (SBRT) is able to deliver high-dose radiation precisely to the
bone metastases and might achieve higher pain response rates [2].
In 2013, we initiated a cohort of patients with bone metastases – the
PRESENT cohort – using the ‘cohort multiple Randomised Controlled
Trial’ (cmRCT) design. The first randomised trial within the cohort is
the VERTICAL study, comparing the effect of SBRT with standard
radiotherapy in patients with metastatic bone disease [3].
Material and Methods
All patients with bone metastases visiting the Radiation Oncology or
Orthopedic Surgery department of the UMC Utrecht are enrolled in a
prospective cohort (PRESENT). Informed consent is obtained for be-
ing offered experimental interventions at random. Patients eligible
for SBRT are randomised: patients allocated to the intervention group
are offered the new treatment; control patients remain uninformed
about the allocation. We compared inclusion rates and flow charts of
the VERTICAL study with a competing classic RCT comparing SBRT
with standard radiotherapy in patients with spinal metastases which
started recruitment at the same time.
Results
Since January 2015, we have randomised 62 patients of which 27 pa-
tients were allocated to the SBRT arm (Figure). After randomisation,
6 patients were ineligible, e.g. due to too many painful lesions. Of
the 21 remaining patients, 16 patients accepted SBRT. Due to rapid
clinical deterioration, six patients were unable to undergo SBRT. In
the competing classic RCT, 11 patients were randomised (Fig. 2)
and all patients allocated to the intervention arm were able to
undergo SBRT.
Conclusion
Comparing both trials (which are ongoing), the VERTICAL trial, using
the cmRCT design, has a higher recruitment rate, and a more
generalizable population as compared to the classic trial. The high
drop-out rate in the intervention arm indicates that also the con-
duct of a cmRCT is challenging in this population.
Trial registration
The Netherlands Trials Register number NL49273.041.14 (PRESENT co-
hort) and NL49316.041.14 (VERTICAL trial). ClinicalTrials.gov registration
number NCT02356497 (PRESENT cohort) and NCT02364115 (VERTICAL
trial). Date of VERTICAL trial registration February 1, 2015.
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The cohort multiple randomized controlled trial (cmRCT)-design
facilitates multiple trials in an efficient cohort structure. The de-
sign poses some methodological and ethical challenges. Here we
present an example of multiple sequential trials within a cmRCT
colorectal cancer cohort (PLCRC) and the challenges that were
encountered.
PLCRC is a Dutch multicenter prospective cohort in which colorectal
cancer patients of all stages are included. Within PLCRC, clinical data,
patient reported outcome measures and biomaterials are collected.
PLCRC was set up to facilitate multiple trials in a real-world setting
according to the cmRCT-design. Currently, two trials are undertaken
within PLCRC: the RECTAL BOOST study and the SPONGE trial. REC-
TAL BOOST evaluates the efficacy of boost radiation in addition to
standard chemoradiation in patients with locally advanced rectal
cancer [1]. SPONGE assesses the impact of the use of a retractor
sponge in laparoscopic colorectal surgery on hospital stay and
postoperative complication [2]. Both trials include rectal cancer pa-
tients from the same study population. Patients may therefore par-
ticipate in both trials.
Ethical issues arising from multiple trials within a cmRCT-design are
related to the consequences of staged-informed consent [3] and in-
clude the following: (1) Participants who have not given consent
for future random selection are considered ineligible for any trial
within the cohort. However, at later points in time, they may want
to reconsider their eligibility for future trials. Currently, no dynamic
informed consent structure within PLCRC exists; (2) Aggregated
Fig. 2 (abstract A14). Flow charts of the VERTICAL trial and the
competing classic RCT
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disclosure of trial results may induce disappointment of not being
selected for any of the interventions in case patients were allocated
to the control group (s); and (3) Broad consent for future, so called
unknown studies, may not always be appropriate since some studies
are known at enrollment.
Methodologically, conducting multiple trials within the same cohort
may result in interacting interventions. Patients having received the
boost intervention potentially have a higher risk on acute toxicity,
which could result in perioperative complications and thereby pro-
longed hospital stay in participants of the SPONGE trial. Interacting
interventions may affect the generalizability and require stratified
random selection. Investigation of interactions requires substantial
sample sizes. Refusal of the intervention may be related to a previ-
ous intervention, which could lead to (selection) bias and possibly
impair generalizability. Also, detection of the outcome could be re-
lated to a previous intervention with hypothetically risk of differen-
tial misclassification.
Conducting multiple trials within a cmRCT cohort brings challenges,
which must be taken into account when initiating a new trial.
Trial registration SPONGE trial Clinicaltrials.gov NCT02574013 REC-
TAL BOOST study Clinicaltrials.gov NCT01951521
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Background
People with severe mental ill health can be a hard to reach popula-
tion for trial recruitment. One reason for this is clinicians’ reluctance
to invite people with severe mental ill health to take part in research.
This may be due to a belief that it would not to be in the person’s
best interest, without checking if this is true.
The TwiCs design might be appropriate since it is easy for participants to
engage with and doesn’t cause ethical dilemmas for the recruiting clin-
ician about whether or not it is in the participant’s best interest to take
part. This promotes service user autonomy. We are piloting this design
Methods
We have set up the Lifestyle Health and Wellbeing Survey to ask people
with severe mental ill health questions about diet, fitness, alcohol and
smoking. Those who respond and are willing to be contacted again will
become part of the Health and Wellbeing cohort. We are looking
at people’s answers to determine whether they are potentially eli-
gible to take part in the SCIMITAR+ randomised controlled trial
(ISRCTN72955454). This trial will test an intervention to help people
quit smoking. Both the Health and Wellbeing cohort and SCIMITAR+
have received research ethics committee approval. If this method of
recruitment proves acceptable to participants we will embed other
trials of lifestyle interventions in the Health and Wellbeing cohort.
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